{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:16:28Z","timestamp":1787663788939,"version":"build-2736575974"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00520-024-08710-0","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T06:02:25Z","timestamp":1721800945000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Opioid analgesic dose and route conversion ratio studies: a scoping review to inform an eDelphi guideline"],"prefix":"10.1007","volume":"32","author":[{"given":"Mellar P.","family":"Davis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Lynn","family":"McPherson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhila","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith A.","family":"Paice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Roeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Declan","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Mercadante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Case","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Satomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Bruera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Ripamonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"issue":"9784","key":"8710_CR1","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1016\/S0140-6736(11)60236-5","volume":"377","author":"RK Portenoy","year":"2011","unstructured":"Portenoy RK (2011) Treatment of cancer pain. Lancet 377(9784):2236\u20132247","journal-title":"Lancet"},{"key":"8710_CR2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.critrevonc.2015.12.011","volume":"99","author":"S Mercadante","year":"2016","unstructured":"Mercadante S, Bruera E (2016) Opioid switching in cancer pain: from the beginning to nowadays. Crit Rev Oncol Hematol 99:241\u2013248","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1\u20132","key":"8710_CR3","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1177\/0310057X211070003","volume":"50","author":"GG Pattullo","year":"2022","unstructured":"Pattullo GG (2022) Opioids in acute pain: towards getting the right balance. Anaesth Intensive Care 50(1\u20132):68\u201380","journal-title":"Anaesth Intensive Care"},{"issue":"3","key":"8710_CR4","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s00520-004-0743-x","volume":"13","author":"D Walsh","year":"2005","unstructured":"Walsh D (2005) Advances in opioid therapy and formulations. Support Care Cancer 13(3):138\u2013144","journal-title":"Support Care Cancer"},{"issue":"2","key":"8710_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1177\/104990910402100213","volume":"21","author":"MP Davis","year":"2004","unstructured":"Davis MP, Walsh D (2004) Epidemiology of cancer pain and factors influencing poor pain control. Am J Hosp Palliat Care 21(2):137\u2013142","journal-title":"Am J Hosp Palliat Care"},{"issue":"1","key":"8710_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s005200100274","volume":"10","author":"Donnelly S, Davis MP, Walsh D, Naughton M, World Health O","year":"2002","unstructured":"Donnelly S, Davis MP, Walsh D, Naughton M, World Health O (2002) Morphine in cancer pain management: a practical guide. Support Care Cancer 10(1):13\u201335","journal-title":"Support Care Cancer"},{"issue":"7","key":"8710_CR7","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1097\/JOM.0000000000000237","volume":"56","author":"KT Hegmann","year":"2014","unstructured":"Hegmann KT, Weiss MS, Bowden K et al (2014) ACOEM practice guidelines: opioids and safety-sensitive work. J Occup Environ Med 56(7):e46-53","journal-title":"J Occup Environ Med"},{"issue":"3","key":"8710_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7103a1","volume":"71","author":"D Dowell","year":"2022","unstructured":"Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R (2022) CDC clinical practice guideline for prescribing opioids for pain - United States, 2022. MMWR Recomm Rep 71(3):1\u201395","journal-title":"MMWR Recomm Rep"},{"issue":"4","key":"8710_CR9","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1517\/14656566.2013.774375","volume":"14","author":"D Santini","year":"2013","unstructured":"Santini D, Lanzetta G, Dell\u2019Aquila E et al (2013) \u2018Old\u2019 and \u2018new\u2019 drugs for the treatment of cancer pain. Expert Opin Pharmacother 14(4):425\u2013433","journal-title":"Expert Opin Pharmacother"},{"issue":"Suppl 1","key":"8710_CR10","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1007\/s100670200029","volume":"21","author":"KH Simpson","year":"2002","unstructured":"Simpson KH (2002) Individual choice of opioids and formulations: strategies to achieve the optimum for the patient. Clin Rheumatol 21(Suppl 1):S5-8","journal-title":"Clin Rheumatol"},{"key":"8710_CR11","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/bs.apha.2017.09.006","volume":"82","author":"GW Pasternak","year":"2018","unstructured":"Pasternak GW (2018) Mu opioid pharmacology: 40 years to the promised land. Adv Pharmacol 82:261\u2013291","journal-title":"Adv Pharmacol"},{"issue":"4","key":"8710_CR12","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/j.1526-4637.2012.01357.x","volume":"13","author":"LR Webster","year":"2012","unstructured":"Webster LR, Fine PG (2012) Review and critique of opioid rotation practices and associated risks of toxicity. Pain Med 13(4):562\u2013570","journal-title":"Pain Med"},{"issue":"3","key":"8710_CR13","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.jpainsymman.2009.06.001","volume":"38","author":"H Knotkova","year":"2009","unstructured":"Knotkova H, Fine PG, Portenoy RK (2009) Opioid rotation: the science and the limitations of the equianalgesic dose table. J Pain Symptom Manage 38(3):426\u2013439","journal-title":"J Pain Symptom Manage"},{"issue":"3","key":"8710_CR14","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jpainsymman.2009.06.002","volume":"38","author":"PG Fine","year":"2009","unstructured":"Fine PG, Portenoy RK (2009) Ad Hoc Expert Panel on Evidence R, Guidelines for opioid R. Establishing \u201cbest practices\u201d for opioid rotation: conclusions of an expert panel. J P Symptom Manag 38(3):418\u2013425","journal-title":"Journal of Pain and Symptom Management"},{"issue":"9","key":"8710_CR15","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1185\/03007990903120158","volume":"25","author":"NE Slatkin","year":"2009","unstructured":"Slatkin NE (2009) Opioid switching and rotation in primary care: implementation and clinical utility. Curr Med Res Opin 25(9):2133\u20132150","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"8710_CR16","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s12325-012-0051-7","volume":"29","author":"SR Nalamachu","year":"2012","unstructured":"Nalamachu SR (2012) Opioid rotation in clinical practice. Adv Ther 29(10):849\u2013863","journal-title":"Adv Ther"},{"issue":"4","key":"8710_CR17","doi-asserted-by":"publisher","first-page":"213","DOI":"10.5055\/jom.2008.0027","volume":"4","author":"A Vadalouca","year":"2008","unstructured":"Vadalouca A, Moka E, Argyra E, Sikioti P, Siafaka I (2008) Opioid rotation in patients with cancer: a review of the current literature. J Opioid Manag 4(4):213\u2013250","journal-title":"J Opioid Manag"},{"issue":"5","key":"8710_CR18","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ejpain.2004.12.003","volume":"9","author":"HC Muller-Busch","year":"2005","unstructured":"Muller-Busch HC, Lindena G, Tietze K, Woskanjan S (2005) Opioid switch in palliative care, opioid choice by clinical need and opioid availability. Eur J Pain 9(5):571\u2013579","journal-title":"Eur J Pain"},{"key":"8710_CR19","unstructured":"Estfan B, LeGrand SB, Walsh D, Lagman RL, Davis MP (2005) Opioid rotation in cancer patients: pros and cons. Oncology (Williston Park) 19(4):511\u2013516; discussion 516\u2013518, 521\u2013513, 527\u2013518"},{"key":"8710_CR20","doi-asserted-by":"crossref","unstructured":"Quigley C (2004) Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev (3):CD004847","DOI":"10.1002\/14651858.CD004847"},{"issue":"1","key":"8710_CR21","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1200\/JCO.2002.20.1.348","volume":"20","author":"RA Indelicato","year":"2002","unstructured":"Indelicato RA, Portenoy RK (2002) Opioid rotation in the management of refractory cancer pain. J Clin Oncol 20(1):348\u2013352","journal-title":"J Clin Oncol"},{"issue":"10","key":"8710_CR22","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1089\/jpm.2022.0266","volume":"25","author":"A Reddy","year":"2022","unstructured":"Reddy A, Sinclair C, Crawford GB et al (2022) Opioid rotation and conversion ratios used by palliative care professionals: an international survey. J Palliat Med 25(10):1557\u20131562","journal-title":"J Palliat Med"},{"issue":"16","key":"8710_CR23","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1016\/j.ejca.2011.06.047","volume":"47","author":"K Moksnes","year":"2011","unstructured":"Moksnes K, Dale O, Rosland JH, Paulsen O, Klepstad P, Kaasa S (2011) How to switch from morphine or oxycodone to methadone in cancer patients? A randomised clinical phase II trial. Eur J Cancer 47(16):2463\u20132470","journal-title":"Eur J Cancer"},{"issue":"4","key":"8710_CR24","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0885-3924(86)80042-2","volume":"1","author":"V Ventafridda","year":"1986","unstructured":"Ventafridda V, Ripamonti C, Bianchi M, Sbanotto A, De Conno F (1986) A randomized study on oral administration of morphine and methadone in the treatment of cancer pain. J Pain Symptom Manag 1(4):203\u2013207","journal-title":"J Pain Symptom Manag"},{"issue":"1","key":"8710_CR25","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1200\/JCO.2004.03.172","volume":"22","author":"E Bruera","year":"2004","unstructured":"Bruera E, Palmer JL, Bosnjak S et al (2004) Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol 22(1):185\u2013192","journal-title":"J Clin Oncol"},{"issue":"4","key":"8710_CR26","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jpainsymman.2007.12.024","volume":"37","author":"S Mercadante","year":"2009","unstructured":"Mercadante S, Ferrera P, Villari P, Casuccio A, Intravaia G, Mangione S (2009) Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit. J Pain Symptom Manage 37(4):632\u2013641","journal-title":"J Pain Symptom Manage"},{"issue":"8","key":"8710_CR27","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/jcph.704","volume":"56","author":"P Glue","year":"2016","unstructured":"Glue P, Cape G, Tunnicliff D et al (2016) Switching opioid-dependent patients from methadone to morphine: safety, tolerability, and methadone pharmacokinetics. J Clin Pharmacol 56(8):960\u2013965","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"8710_CR28","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/S0885-3924(99)00049-4","volume":"18","author":"B Gagnon","year":"1999","unstructured":"Gagnon B, Bruera E (1999) Differences in the ratios of morphine to methadone in patients with neuropathic pain versus non-neuropathic pain. J Pain Symptom Manage 18(2):120\u2013125","journal-title":"J Pain Symptom Manage"},{"issue":"2","key":"8710_CR29","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1136\/bmjspcare-2018-001645","volume":"10","author":"B Lukin","year":"2020","unstructured":"Lukin B, Greenslade J, Kearney AM et al (2020) Conversion of other opioids to methadone: a retrospective comparison of two methods. BMJ Support Palliat Care 10(2):201\u2013204","journal-title":"BMJ Support Palliat Care"},{"issue":"11","key":"8710_CR30","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1089\/jpm.2013.0222","volume":"16","author":"W Rhondali","year":"2013","unstructured":"Rhondali W, Tremellat F, Ledoux M, Ciais JF, Bruera E, Filbet M (2013) Methadone rotation for cancer patients with refractory pain in a palliative care unit: an observational study. J Palliat Med 16(11):1382\u20131387","journal-title":"J Palliat Med"},{"issue":"6","key":"8710_CR31","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jpainsymman.2008.05.016","volume":"37","author":"MA Benitez-Rosario","year":"2009","unstructured":"Benitez-Rosario MA, Salinas-Martin A, Aguirre-Jaime A, Perez-Mendez L, Feria M (2009) Morphine-methadone opioid rotation in cancer patients: analysis of dose ratio predicting factors. J Pain Symptom Manage 37(6):1061\u20131068","journal-title":"J Pain Symptom Manage"},{"issue":"8","key":"8710_CR32","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1089\/jpm.2007.0285","volume":"11","author":"PW Walker","year":"2008","unstructured":"Walker PW, Palla S, Pei BL et al (2008) Switching from methadone to a different opioid: what is the equianalgesic dose ratio? J Palliat Med 11(8):1103\u20131108","journal-title":"J Palliat Med"},{"issue":"2","key":"8710_CR33","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1191\/0269216303pm696oa","volume":"17","author":"DM Tse","year":"2003","unstructured":"Tse DM, Sham MM, Ng DK, Ma HM (2003) An ad libitum schedule for conversion of morphine to methadone in advanced cancer patients: an open uncontrolled prospective study in a Chinese population. Palliat Med 17(2):206\u2013211","journal-title":"Palliat Med"},{"issue":"11","key":"8710_CR34","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1200\/JCO.2001.19.11.2898","volume":"19","author":"S Mercadante","year":"2001","unstructured":"Mercadante S, Casuccio A, Fulfaro F et al (2001) Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol 19(11):2898\u20132904","journal-title":"J Clin Oncol"},{"issue":"8","key":"8710_CR35","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1089\/jpm.2012.0434","volume":"16","author":"MS Chatham","year":"2013","unstructured":"Chatham MS, Dodds Ashley ES, Svengsouk JS, Juba KM (2013) Dose ratios between high dose oral morphine or equivalents and oral methadone. J Palliat Med 16(8):947\u2013950","journal-title":"J Palliat Med"},{"issue":"2","key":"8710_CR36","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jpainsymman.2006.02.010","volume":"32","author":"OM Fredheim","year":"2006","unstructured":"Fredheim OM, Borchgrevink PC, Hegrenaes L, Kaasa S, Dale O, Klepstad P (2006) Opioid switching from morphine to methadone causes a minor but not clinically significant increase in QTc time: a prospective 9-month follow-up study. J Pain Symptom Manage 32(2):180\u2013185","journal-title":"J Pain Symptom Manage"},{"issue":"2","key":"8710_CR37","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00520-009-0649-8","volume":"18","author":"DI Cubero","year":"2010","unstructured":"Cubero DI, del Giglio A (2010) Early switching from morphine to methadone is not improved by acetaminophen in the analgesia of oncologic patients: a prospective, randomized, double-blind, placebo-controlled study. Support Care Cancer 18(2):235\u2013242","journal-title":"Support Care Cancer"},{"issue":"4","key":"8710_CR38","doi-asserted-by":"publisher","DOI":"10.1097\/PR9.0000000000000979","volume":"6","author":"GA Moreira de Barros","year":"2021","unstructured":"Moreira de Barros GA, Baradelli R, Rodrigues DG et al (2021) Use of methadone as an alternative to morphine for chronic pain management: a noninferiority retrospective observational study. Pain Rep 6(4):e979","journal-title":"Pain Rep"},{"issue":"10","key":"8710_CR39","doi-asserted-by":"publisher","first-page":"3216","DOI":"10.1200\/JCO.1998.16.10.3216","volume":"16","author":"C Ripamonti","year":"1998","unstructured":"Ripamonti C, Groff L, Brunelli C, Polastri D, Stavrakis A, De Conno F (1998) Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol 16(10):3216\u20133221","journal-title":"J Clin Oncol"},{"issue":"10","key":"8710_CR40","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1200\/JCO.1999.17.10.3307","volume":"17","author":"S Mercadante","year":"1999","unstructured":"Mercadante S, Casuccio A, Calderone L (1999) Rapid switching from morphine to methadone in cancer patients with poor response to morphine. J Clin Oncol 17(10):3307\u20133312","journal-title":"J Clin Oncol"},{"issue":"5","key":"8710_CR41","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1177\/0269216311406577","volume":"25","author":"S Mercadante","year":"2011","unstructured":"Mercadante S, Caraceni A (2011) Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review. Palliat Med 25(5):504\u2013515","journal-title":"Palliat Med"},{"issue":"1","key":"8710_CR42","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/0304-3959(95)00082-8","volume":"64","author":"A Woodhouse","year":"1996","unstructured":"Woodhouse A, Hobbes AFT, Mather LE, Gibson M (1996) A comparison of morphine, pethidine and fentanyl in the postsurgical patient-controlled analgesia environment. Pain 64(1):115\u2013121","journal-title":"Pain"},{"key":"8710_CR43","doi-asserted-by":"crossref","unstructured":"Miller MG, McCarthy N, O\u2019Boyle CA, Kearney M (1999) Continuous subcutaneous infusion of morphine vs. hydromorphone: a controlled trial. J Pain Symptom Manage 18(1):9\u201316","DOI":"10.1016\/S0885-3924(99)00036-6"},{"issue":"4","key":"8710_CR44","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/j.1600-0773.1990.tb00838.x","volume":"67","author":"E Kalso","year":"1990","unstructured":"Kalso E, Vainio A, Mattila MJ, Rosenberg PH, Seppala T (1990) Morphine and oxycodone in the management of cancer pain: plasma levels determined by chemical and radioreceptor assays. Pharmacol Toxicol 67(4):322\u2013328","journal-title":"Pharmacol Toxicol"},{"issue":"1","key":"8710_CR45","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0304-3959(97)00072-9","volume":"73","author":"T Heiskanen","year":"1997","unstructured":"Heiskanen T, Kalso E (1997) Controlled-release oxycodone and morphine in cancer related pain. Pain 73(1):37\u201345","journal-title":"Pain"},{"issue":"3","key":"8710_CR46","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/cpt196783415","volume":"8","author":"WT Beaver","year":"1967","unstructured":"Beaver WT, Wallenstein SL, Houde RW, Rogers A (1967) A clinical comparison of the analgesic effects of methadone and morphine administered intramuscularly, and of orally and parenterally administered methadone. Clin Pharmacol Ther 8(3):415\u2013426","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"8710_CR47","doi-asserted-by":"publisher","first-page":"567","DOI":"10.5055\/jom.2022.0751","volume":"18","author":"HC Dinges","year":"2022","unstructured":"Dinges HC, Schubert AK, Rucker G et al (2022) Equianalgesic potency ratios of opioids used in patient-controlled analgesia: a network meta-analysis. J Opioid Manag 18(6):567\u2013586","journal-title":"J Opioid Manag"},{"issue":"2","key":"8710_CR48","doi-asserted-by":"publisher","first-page":"537","DOI":"10.21037\/apm.2020.03.05","volume":"9","author":"ML McPherson","year":"2020","unstructured":"McPherson ML (2020) Why equianalgesic tables are only part of the answer to equianalgesia. Ann Palliat Med 9(2):537\u2013541","journal-title":"Ann Palliat Med"},{"issue":"9","key":"8710_CR49","first-page":"135","volume":"115","author":"M Schuster","year":"2018","unstructured":"Schuster M, Bayer O, Heid F, Laufenberg-Feldmann R (2018) Opioid rotation in cancer pain treatment. Dtsch Arztebl Int 115(9):135\u2013142","journal-title":"Dtsch Arztebl Int"},{"key":"8710_CR50","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.2147\/JPR.S170269","volume":"11","author":"E Treillet","year":"2018","unstructured":"Treillet E, Laurent S, Hadjiat Y (2018) Practical management of opioid rotation and equianalgesia. J Pain Res 11:2587\u20132601","journal-title":"J Pain Res"},{"key":"8710_CR51","doi-asserted-by":"crossref","unstructured":"Houde RW, Wallenstein SL, Rogers A (1960) Clinical pharmacology of analgesics. 1. A method of assaying analgesic effect. Clin Pharmacol Ther 1:163\u2013174","DOI":"10.1002\/cpt196012163"},{"issue":"6","key":"8710_CR52","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/cpt196676740","volume":"7","author":"WT Beaver","year":"1966","unstructured":"Beaver WT, Wallenstein SL, Houde RW, Rogers A (1966) A comparison of the analgesic effects of pentazocine and morphine in patients with cancer. Clin Pharmacol Ther 7(6):740\u2013751","journal-title":"Clin Pharmacol Ther"},{"issue":"1\u20132","key":"8710_CR53","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.pain.2009.04.012","volume":"144","author":"T Heiskanen","year":"2009","unstructured":"Heiskanen T, Matzke S, Haakana S, Gergov M, Vuori E, Kalso E (2009) Transdermal fentanyl in cachectic cancer patients. Pain 144(1\u20132):218\u2013222","journal-title":"Pain"},{"issue":"5","key":"8710_CR54","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1248\/bpb.b13-00717","volume":"37","author":"H Takahashi","year":"2014","unstructured":"Takahashi H, Chiba T, Tairabune T et al (2014) A retrospective study on the influence of nutritional status on pain management in cancer patients using the transdermal fentanyl patch. Biol Pharm Bull 37(5):853\u2013857","journal-title":"Biol Pharm Bull"},{"issue":"1","key":"8710_CR55","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1177\/1078155220929415","volume":"27","author":"LD Jackson","year":"2021","unstructured":"Jackson LD, Wortzman R, Chua D, Selby D (2021) Opioid rotation from transdermal fentanyl to continuous subcutaneous hydromorphone in a cachectic patient: a case report and review of the literature. J Oncol Pharm Pract 27(1):238\u2013243","journal-title":"J Oncol Pharm Pract"},{"issue":"e2","key":"8710_CR56","doi-asserted-by":"publisher","first-page":"e184","DOI":"10.1136\/bmjspcare-2019-001935","volume":"12","author":"SA Alsirafy","year":"2022","unstructured":"Alsirafy SA, Alabdullateef SH, Elyamany AM, Hassan AD, Almashiakhi M (2022) Transdermal fentanyl to parenteral morphine route switch and drug rotation in refractory cancer cachexia. BMJ Support Palliat Care 12(e2):e184\u2013e186","journal-title":"BMJ Support Palliat Care"},{"key":"8710_CR57","doi-asserted-by":"publisher","first-page":"751","DOI":"10.2147\/TCRM.S79374","volume":"11","author":"M Suno","year":"2015","unstructured":"Suno M, Endo Y, Nishie H, Kajizono M, Sendo T, Matsuoka J (2015) Refractory cachexia is associated with increased plasma concentrations of fentanyl in cancer patients. Ther Clin Risk Manag 11:751\u2013757","journal-title":"Ther Clin Risk Manag"},{"issue":"8","key":"8710_CR58","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/jcph.112","volume":"53","author":"T Naito","year":"2013","unstructured":"Naito T, Tashiro M, Ishida T, Ohnishi K, Kawakami J (2013) Cancer cachexia raises the plasma concentration of oxymorphone through the reduction of CYP3A but not CYP2D6 in oxycodone-treated patients. J Clin Pharmacol 53(8):812\u2013818","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"8710_CR59","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s00228-016-2116-z","volume":"72","author":"H Sato","year":"2016","unstructured":"Sato H, Naito T, Ishida T, Kawakami J (2016) Relationships between oxycodone pharmacokinetics, central symptoms, and serum interleukin-6 in cachectic cancer patients. Eur J Clin Pharmacol 72(12):1463\u20131470","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"8710_CR60","doi-asserted-by":"publisher","first-page":"e2042","DOI":"10.1002\/onco.13953","volume":"26","author":"N Reizine","year":"2021","unstructured":"Reizine N, Danahey K, Schierer E et al (2021) Impact of CYP2D6 pharmacogenomic status on pain control among opioid-treated oncology patients. Oncologist 26(11):e2042\u2013e2052","journal-title":"Oncologist"},{"issue":"4","key":"8710_CR61","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.amjopharm.2004.12.005","volume":"2","author":"BJ Cusack","year":"2004","unstructured":"Cusack BJ (2004) Pharmacokinetics in older persons. Am J Geriatr Pharmacother 2(4):274\u2013302","journal-title":"Am J Geriatr Pharmacother"},{"issue":"7","key":"8710_CR62","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.2215\/CJN.00340118","volume":"13","author":"TN Lea-Henry","year":"2018","unstructured":"Lea-Henry TN, Carland JE, Stocker SL, Sevastos J, Roberts DM (2018) Clinical pharmacokinetics in kidney disease: fundamental principles. Clin J Am Soc Nephrol 13(7):1085\u20131095","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"8710_CR63","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.bja.2018.12.010","volume":"122","author":"MS Avidan","year":"2019","unstructured":"Avidan MS, Ioannidis JPA, Mashour GA (2019) Independent discussion sections for improving inferential reproducibility in published research. Br J Anaesth 122(4):413\u2013420","journal-title":"Br J Anaesth"},{"issue":"3","key":"8710_CR64","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1080\/15360288.2023.2194873","volume":"37","author":"RY Wen","year":"2023","unstructured":"Wen RY, Edmonds KP, Atayee RS (2023) Comparing national methadone equianalgesic tools. J Pain Palliat Care Pharmacother 37(3):246\u2013250","journal-title":"J Pain Palliat Care Pharmacother"},{"issue":"10","key":"8710_CR65","doi-asserted-by":"publisher","first-page":"536","DOI":"10.5694\/j.1326-5377.2000.tb139323.x","volume":"173","author":"OT Ayonrinde","year":"2000","unstructured":"Ayonrinde OT, Bridge DT (2000) The rediscovery of methadone for cancer pain management. Med J Aust 173(10):536\u2013540","journal-title":"Med J Aust"},{"issue":"1","key":"8710_CR66","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1023\/A:1008263910494","volume":"9","author":"C Ripamonti","year":"1998","unstructured":"Ripamonti C, De Conno F, Groff L et al (1998) Equianalgesic dose\/ratio between methadone and other opioid agonists in cancer pain: comparison of two clinical experiences. Ann Oncol 9(1):79\u201383","journal-title":"Ann Oncol"}],"updated-by":[{"DOI":"10.1007\/s00520-024-08820-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000}}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08710-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-024-08710-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08710-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T11:20:31Z","timestamp":1724325631000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-024-08710-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":66,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["8710"],"URL":"https:\/\/doi.org\/10.1007\/s00520-024-08710-0","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00520-024-08820-9","asserted-by":"object"}]},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,24]]},"assertion":[{"value":"21 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00520-024-08820-9","URL":"https:\/\/doi.org\/10.1007\/s00520-024-08820-9","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"542"}}